Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment.
Nenhuma Miniatura Disponível
Data
2018
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
The development of new strategies to attenuate exercise-induced muscle damage may be helpful for training regimens. The
aim of this study was to determine whether a oral formulation of
angiotensin Ang-(1-7)[HPβCD/Ang-(1-7)] is effective to reduce
pain, and muscle damage markers after eccentric-overload exercise. HPβCD (Placebo) and HPβCD/Ang-(1-7) (Ang-(1-7) group
were treated for 7 days (one capsule/day). The pain was measured by visual analogue scale, maximal strength (MS) using force
platform. Blood samples were collected for cytokines and creatine kinase (CK) analysis. The Ang-(1-7)-treated group reported
less pain immediately (3.46± 0.64 vs. placebo 3.80± 0.77 cm)
and 24h after exercise (3.07±0.71 vs. 3.73±0.58cm placebo)
and higher MS at 24h (24±12N) and 48h (30±15N) vs. placebo
(-8 ± 9 N and -10 ± 9 N). The CK for Ang-(1-7) (0.5 ± 0.1 and
0.9±0.2 U/L) were lower at 48 and 72h vs. placebo (fold changes of 1.7±0.5 and 1.5±0.3 U/L). The TNF-α level was lower in the
treated group post-exercise (38 ± 2.5 pg/ml) vs. placebo
(45 ± 2.9 pg/ml) but no significant changes were observed for
IL-6 and IL-10. Our data indicate that treatment with Ang-(1-7)
may attenuate pain, some of the muscle damage markers and
improves performance following eccentric exercise.
Descrição
Palavras-chave
Physical performance, Muscular damage
Citação
OLIVEIRA, L. K. B. et al. Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment. International Journal of Sports Medicine, v. 39, n. 10, p. 743-748, 2018. Disponível em: <https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-0633-8892>. Acesso em: 20 fev. 2019.